

CLINICAL TRIAL

STAR - NCT03496012

Research



A Randomised, Open Label, Outcomes-Assessor Masked, Prospective, Parallel Controlled Group, Phase 3 Clinical Trial Of Retinal Gene Therapy For Choroideremia Using An Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1)

Rare Eye Disease concerned by the trial :
Choroideremia

Status of the trial : prolonged, not recruiting
Orphan drug recognition : Yes

Inclusion criteria : [click here to see detailed criteria](#)

Exclusion criteria : [click here to see detailed criteria](#)



Inclusion opening date : 01/01/2018



Inclusion closing date (previsional) : 31/12/2018

Children



Adults



Within ERN-EYE members



Principal location of the trial :

Center for Ophthalmic Research, University Hospital of Tübingen

Elfriede-Aulhorn-Str. 7
72076 Tübingen
Germany

[Contact details](#)



Principal investigator name :

Prof. Dr. Dr. Dominik Fischer



Other investigators :


University Hospital of Tübingen

Tübingen, Germany

Prof. Dr. med. Karl Ulrich Bartz-Schmidt

Radboud University Medical Center,

Nijmegen, Netherlands



Funder type : Drug company - Industry

[More informations](#)